Takeda Pharmaceutical Company Limited and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, have formed a partnership to identify and develop medical innovations. Takeda will also invest $25 million over five years in BioMotic. This investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of immunology, inflammation,and cardio-metabolic diseases.

Launched in 2012, The Harrington Project for Discovery & Development is a $250-million national initiative organized through University Hospitals in Cleveland, Ohio, which consists of the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator. The aim of the project is to identify, fund, and advance the development of medical breakthroughs from research institutions and disease foundations throughout the United States.This initiative targets physician-scientist discoveries and provides bench-to-bedside clinical insights into disorders where there is high unmet medical demand.  

Source: Takeda Pharmaceutical